Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology

Xue-Jun LIANG; Li-Ying GONG; Fei ZHOU; De-Min ZHOU; Jing-Jing ZHU.
Journal of Peking University(Health Sciences) ; (6): 797-804, 2019.
Artículo en Zh | WPRIM | ID: wpr-941891

Documentos relacionados

  1. [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology].
  2. Activity of trastuzumab emtansine (T-DM1) in 3D cell culture.
  3. Direct In Vivo Comparison of <sup>99m</sup>Tc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy.
  4. Effectiveness of [<sup>67</sup>Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer.
  5. A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM).
  6. Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain.
  7. Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer.
  8. Decreased HER2 expression in endometrial cancer following anti-HER2 therapy.
  9. Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy.
  10. Optical biosensor based on weak value amplification for the high sensitivity detection of Pertuzumab in combination with Trastuzumab binding to the extracellular domain of HER2.